サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298369

抗肥満薬市場：薬剤タイプ別、作用機序別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年

Anti-Obesity Drugs Market By Drug Type, By Mechanism of Action, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 447 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
抗肥満薬市場：薬剤タイプ別、作用機序別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年
出版日: 2023年04月01日
発行: Allied Market Research
ページ情報: 英文 447 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗肥満薬市場は、2022年に16億536万米ドルと評価され、2023年から2032年までのCAGRは10.7％を示し、2032年には44億3,934万米ドルに達すると推定されます。

肥満とは、健康に悪影響を及ぼすほど過剰な体脂肪が蓄積した医学的状態を指します。一般に肥満とは、体格指数（BMI）が30以上であることと定義されます。先進国および発展途上国において、最大かつ最も急速に増加している公衆衛生問題として広く認識されています。抗肥満薬は、太りすぎの人を助けるために処方される薬です。これらの薬は、食欲を抑えたり、代謝を高めたり、食物からの脂肪の吸収を阻害したりすることで効果を発揮します。一般的に処方される抗肥満薬には、フェンテルミン、シブトラミン、オルリスタット、リラグルチドなどがあります。

Anti-Obesity Drugs Market-IMG1

抗肥満薬市場の成長を促進する主な要因は、肥満の有病率の大幅な上昇、過体重または肥満に関連する健康リスクの急増、肥満と2型糖尿病の両方を標的とするいくつかの潜在的な薬剤分子に関する研究開発活動の増加です。例えば、ノボノルディスクは2021年6月、米国食品医薬品局（FDA）が慢性的な体重管理を目的とした週1回投与のセマグルチド2.4mg注射剤「ウェゴビー」を米国で承認したと発表しました。さらに、肥満に関する健康問題を人々に認識させるための政府による取り組みの増加や、抗肥満薬の大規模生産のための政府および民間団体からの資金提供の増加は、市場の成長を促進する主要市場プレーヤーにとって新たな市場の可能性を開く可能性があります。

しかし、厳しい医薬品承認政策と代替療法の利用可能性が市場成長の妨げとなっています。逆に、肥満と2型糖尿病の有病率の増加は、市場の研究者やベンダーに肥満と2型糖尿病の両方に対抗できる薬剤の研究を促しています。したがって、肥満人口の増加、不健康な食習慣の増加、座りがちなライフスタイルは、抗肥満薬に新たな市場の可能性を開く可能性があり、予測期間中の市場成長に有利な機会を提供すると期待されます。

北米は2021年の抗肥満薬市場シェアの大半を占め、予測期間中も支配的な地位を維持すると予測されています。抗肥満薬市場は主に、肥満人口の増加と抗肥満薬に対する高額なヘルスケア支出が牽引しています。さらに、肥満に関連する重篤な慢性疾患に対する人々の意識の高まりや、主要な市場参入企業による研究開発活動への投資の増加に起因する臨床試験数の急増が、市場の成長を促進すると予想されます。

アジア太平洋地域は、ヘルスケア支出の増加と、主要市場参入企業による肥満治療新薬開発のための研究開発活動の急増により、予測期間中に最も速いCAGRを記録すると予想されます。さらに、インド、中国、韓国などの新興諸国における肥満の有病率の増加や抗肥満薬に対する意識の高まりも、同地域の抗肥満薬市場の成長に寄与しています。

しかし、同市場は、肥満の有病率の上昇により、パンデミック後は回復に向かうと予想されます。また、パンデミック期間中に不健康で座りっぱなしのライフスタイルを採用する人が増加したことも、市場の成長に拍車をかけると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • 肥満の有病率の増加
      • パイプライン薬剤数の増加
      • 臨床試験数の増加
    • 阻害要因
      • 抗肥満薬の副作用の可能性
    • 機会
      • 新興経済諸国における高い成長の可能性
  • COVID-19市場への影響分析

第4章 肥満治療薬市場：薬剤タイプ別

  • 概要
    • 市場規模および予測
  • 処方薬
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • OTC薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 抗肥満薬市場：作用機序別

  • 概要
    • 市場規模および予測
  • 中枢性抗肥満薬
    • 主要市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場シェア分析：国別
  • 末梢性抗肥満薬
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 抗肥満薬市場：投与経路別

  • 概要
    • 市場規模および予測
  • 経口投与ルート
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 皮下ルート
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 抗肥満薬市場：流通チャネル別

  • 概要
    • 市場規模および予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • オンライン薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第8章 抗肥満薬市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：薬剤タイプ別
    • 市場規模・予測：作用機序別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：薬剤タイプ別
    • 市場規模・予測：作用機序別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：薬剤タイプ別
    • 市場規模・予測：作用機序別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：薬剤タイプ別
    • 市場規模・予測：作用機序別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 南アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他の地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：作用機序別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2022年

第10章 企業プロファイル

  • Currax Pharmaceuticals LLC
  • KVK Tech Inc.
  • Gelesis Holdings, INC.
  • Vivus LLC.
  • CHEPLAPHARM Arzneimittel GmbH
  • Pfizer Inc.
  • Rhythm Pharmaceuticals
  • Novo Nordisk A/S
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
図表

LIST OF TABLES

  • TABLE 01. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 05. ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 08. ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. ANTI-OBESITY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. CANADA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. UK ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 47. UK ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. UK ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ITALY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ITALY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 51. ITALY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 58. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. CHINA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 71. CHINA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 72. CHINA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. CHINA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. INDIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 79. INDIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 80. INDIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 95. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 96. BRAZIL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 97. BRAZIL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 104. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 105. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 111. CURRAX PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 112. CURRAX PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 113. CURRAX PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 114. CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 115. CURRAX PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 116. KVK TECH INC.: KEY EXECUTIVES
  • TABLE 117. KVK TECH INC.: COMPANY SNAPSHOT
  • TABLE 118. KVK TECH INC.: PRODUCT SEGMENTS
  • TABLE 119. KVK TECH INC.: SERVICE SEGMENTS
  • TABLE 120. KVK TECH INC.: PRODUCT PORTFOLIO
  • TABLE 121. GELESIS HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 122. GELESIS HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 123. GELESIS HOLDINGS, INC.: SERVICE SEGMENTS
  • TABLE 124. GELESIS HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 125. GELESIS HOLDINGS, INC.: KEY STRATERGIES
  • TABLE 126. VIVUS LLC.: KEY EXECUTIVES
  • TABLE 127. VIVUS LLC.: COMPANY SNAPSHOT
  • TABLE 128. VIVUS LLC.: PRODUCT SEGMENTS
  • TABLE 129. VIVUS LLC.: SERVICE SEGMENTS
  • TABLE 130. VIVUS LLC.: PRODUCT PORTFOLIO
  • TABLE 131. VIVUS LLC.: KEY STRATERGIES
  • TABLE 132. CHEPLAPHARM ARZNEIMITTEL GMBH: KEY EXECUTIVES
  • TABLE 133. CHEPLAPHARM ARZNEIMITTEL GMBH: COMPANY SNAPSHOT
  • TABLE 134. CHEPLAPHARM ARZNEIMITTEL GMBH: SERVICE SEGMENTS
  • TABLE 135. CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCT PORTFOLIO
  • TABLE 136. PFIZER INC.: KEY EXECUTIVES
  • TABLE 137. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 139. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140. RHYTHM PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 141. RHYTHM PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 142. RHYTHM PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 143. RHYTHM PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 144. RHYTHM PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 145. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 146. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 147. NOVO NORDISK A/S: PRODUCT SEGMENTS
  • TABLE 148. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 149. NOVO NORDISK A/S: KEY STRATERGIES
  • TABLE 150. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 151. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 152. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 153. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 154. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 155. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 156. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 157. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 158. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. ANTI-OBESITY DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTI-OBESITY DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ANTI-OBESITY DRUGS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTI-OBESITY DRUGS MARKET
  • FIGURE 10. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. ANTI-OBESITY DRUGS MARKET BY REGION, 2022
  • FIGURE 24. U.S. ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. INDIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: ANTI-OBESITY DRUGS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. GELESIS HOLDINGS, INC.: NET REVENUE, 2020-2021 ($MILLION)
  • FIGURE 51. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. RHYTHM PHARMACEUTICALS: NET REVENUE, 2021-2022 ($MILLION)
  • FIGURE 55. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 62. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A03823

The anti-obesity drugs market valued for $1,605.36 million in 2022 and is estimated to reach $4,439.34 million by 2032, exhibiting a CAGR of 10.7% from 2023 to 2032. Obesity is a medical condition in which excess body fat is accumulated to an extent that it causes a negative effect on health. It is generally defined as having a body mass index (BMI) of 30 or greater. It is widely recognized as the largest and fastest-growing public health problem in developed and developing countries. Anti-obesity drugs are medications prescribed to help people who are overweight. These drugs work by suppressing appetite, increasing metabolism, or blocking the absorption of fat from food. Some of the commonly prescribed anti-obesity drugs include phentermine, sibutramine, orlistat, and liraglutide.

Anti-Obesity Drugs Market - IMG1

The key factor that drives the growth of the anti-obesity drugs market is significant rise in the prevalence rate of obesity, surge in health risks associated with being overweight or obese and increase in number of research and development activities on several potential drug molecules that target both obesity and type 2 diabetes mellitus. For instance, in June 2021 Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Wegovy for once weekly semaglutide 2.4 mg injection in the U.S. for chronic weight management. Furthermore, increase in number of initiatives taken by government to make people aware about health-related issues with obesity and rise in funding from government and private bodies for large-scale production of anti-obesity drugs, may open up new market potential for key market players that drive the growth of the market.

However, stringent drug approval policies and the availability of alternative therapies hamper market growth. Conversely, rise in the prevalence of obesity and type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and type 2 diabetes. Hence, increase in obese population, rise in unhealthy eating habits, and sedentary lifestyles may open up new market potentials for anti-obesity drugs and are expected to provide lucrative opportunity for the growth of the market during the forecast period.

North America accounted for a majority of the anti-obesity drug market share in 2021 and is anticipated to remain dominant during the forecast period. The anti-obesity drugs market is mainly driven by the increase in obese population and high healthcare expenditure on anti-obesity drugs. Furthermore, increase in awareness among the population regarding severe chronic diseases related to obesity and surge in number of clinical trials owing to a rise in investment by key market players in R&D activities are expected to fuel the market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to increase in healthcare expenditure and surge in R&D activities by key market players for the development of new drugs to treat obesity in the Asia-Pacific region. Furthermore, the increase in prevalence of obesity and rise in awareness about anti-obesity drugs in developing countries such as India, China, and South Korea contribute toward the growth of the anti-obesity drug market in this region.

However, the market is expected to witness a recovery post pandemic owing to rise in prevalence of obesity. In addition, an increase in number of people adopting unhealthy and sedentary lifestyles during the pandemic is anticipated to fuel the growth of the market.

The anti-obesity drugs market is segmented on the basis of drug type, mechanism of action, route of administration, distribution channel, and region. By drug type, the market is bifurcated into prescription drugs, and over the counter drugs. By mechanism of action, the market is divided into centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs. By route of administration, the market is categorized into oral route and subcutaneous route. By distribution channel, the market is classified into hospital pharmacies, retail pharmacies and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in the anti-obesity drugs market are: Currax Pharmaceuticals LLC, Pfizer Inc, Novo Nordisk A/S, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, KVK Tech Inc, CHEPLAPHARM Arzneimittel GmbH, Gelesis Holdings, INC., VIVUS LLC, and Rhythm Pharmaceuticals.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anti-obesity drugs market analysis from 2022 to 2032 to identify the prevailing anti-obesity drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anti-obesity drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as anti-obesity drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Prescription Drugs
  • Over The Counter Drugs

By Mechanism of Action

  • Centrally Acting Anti-Obesity Drugs
  • Peripherally Acting Anti-Obesity Drugs

By Route of Administration

  • Oral Route
  • Subcutaneous Route

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Pfizer Inc.
  • Novo Nordisk A/S
  • Boehringer Ingelheim International GmbH
  • KVK Tech Inc.
  • Gelesis Holdings, INC.
  • Vivus LLC.
  • Currax Pharmaceuticals LLC
  • GlaxoSmithKline plc
  • CHEPLAPHARM Arzneimittel GmbH
  • Rhythm Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of obesity
      • 3.4.1.2. Increase in number of drugs in pipeline
      • 3.4.1.3. Increase in number of clinical trials
    • 3.4.2. Restraints
      • 3.4.2.1. Potential side effects of anti-obesity drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Prescription Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Over The Counter Drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Centrally Acting Anti-Obesity Drugs
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Peripherally Acting Anti-Obesity Drugs
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Oral Route
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Subcutaneous Route
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Pharmacies
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: ANTI-OBESITY DRUGS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Drug Type
    • 8.2.3. Market size and forecast, by Mechanism of Action
    • 8.2.4. Market size and forecast, by Route of Administration
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Drug Type
      • 8.2.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.1.4. Market size and forecast, by Route of Administration
      • 8.2.6.1.5. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Drug Type
      • 8.2.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.2.4. Market size and forecast, by Route of Administration
      • 8.2.6.2.5. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Drug Type
      • 8.2.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.3.4. Market size and forecast, by Route of Administration
      • 8.2.6.3.5. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Drug Type
    • 8.3.3. Market size and forecast, by Mechanism of Action
    • 8.3.4. Market size and forecast, by Route of Administration
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Drug Type
      • 8.3.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.1.4. Market size and forecast, by Route of Administration
      • 8.3.6.1.5. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Drug Type
      • 8.3.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.2.4. Market size and forecast, by Route of Administration
      • 8.3.6.2.5. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Drug Type
      • 8.3.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.3.4. Market size and forecast, by Route of Administration
      • 8.3.6.3.5. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Drug Type
      • 8.3.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.4.4. Market size and forecast, by Route of Administration
      • 8.3.6.4.5. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Drug Type
      • 8.3.6.5.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.5.4. Market size and forecast, by Route of Administration
      • 8.3.6.5.5. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Drug Type
      • 8.3.6.6.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.6.4. Market size and forecast, by Route of Administration
      • 8.3.6.6.5. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Drug Type
    • 8.4.3. Market size and forecast, by Mechanism of Action
    • 8.4.4. Market size and forecast, by Route of Administration
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Drug Type
      • 8.4.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.1.4. Market size and forecast, by Route of Administration
      • 8.4.6.1.5. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Drug Type
      • 8.4.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.2.4. Market size and forecast, by Route of Administration
      • 8.4.6.2.5. Market size and forecast, by Distribution Channel
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Drug Type
      • 8.4.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.3.4. Market size and forecast, by Route of Administration
      • 8.4.6.3.5. Market size and forecast, by Distribution Channel
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Drug Type
      • 8.4.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.4.4. Market size and forecast, by Route of Administration
      • 8.4.6.4.5. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Drug Type
      • 8.4.6.5.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.5.4. Market size and forecast, by Route of Administration
      • 8.4.6.5.5. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Drug Type
      • 8.4.6.6.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.6.4. Market size and forecast, by Route of Administration
      • 8.4.6.6.5. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Drug Type
    • 8.5.3. Market size and forecast, by Mechanism of Action
    • 8.5.4. Market size and forecast, by Route of Administration
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Drug Type
      • 8.5.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.1.4. Market size and forecast, by Route of Administration
      • 8.5.6.1.5. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Drug Type
      • 8.5.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.2.4. Market size and forecast, by Route of Administration
      • 8.5.6.2.5. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Drug Type
      • 8.5.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.3.4. Market size and forecast, by Route of Administration
      • 8.5.6.3.5. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Drug Type
      • 8.5.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.4.4. Market size and forecast, by Route of Administration
      • 8.5.6.4.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Currax Pharmaceuticals LLC
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Key strategic moves and developments
  • 10.2. KVK Tech Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
  • 10.3. Gelesis Holdings, INC.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
    • 10.3.7. Key strategic moves and developments
  • 10.4. Vivus LLC.
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Key strategic moves and developments
  • 10.5. CHEPLAPHARM Arzneimittel GmbH
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
  • 10.6. Pfizer Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Rhythm Pharmaceuticals
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
    • 10.7.7. Key strategic moves and developments
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. GlaxoSmithKline plc
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Boehringer Ingelheim International GmbH
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments